Bezafibrate is a lipid?lowering agent and one of the fibric acid derivatives. It is relatively safe and well tolerated and adverse reactions to bezafibrate have largely been restricted to gastrointestinal distrubances. But a few cases of rhabdomyolysis after bezafibrate administration have been reported and recently we experienced bezafibrate-induced rhabdomyolysis in patients with chronic renal failure. So we report this case with the bone scan finding and the literature review We believe that this is the first case report of bezafibrate-induced rhabdomyolysis in Korea.